Skip to main content
. 2015 Dec 10;7:381–388. doi: 10.2147/BCTT.S94516

Figure 1.

Figure 1

Kaplan–Meier estimates of relapse-free survival.

Note: (A) shows the predicted relapse-free survival (RFS) (in months, x-axis) for the three groups with differential estrogen receptor (ER) Allred scores (A=0–2, B=3–5, C=6–8); hazard ratio: Pre_chemo_ER_Allred_A 8.145, confidence interval 1.59–40.85, P<0.01; Pre_chemo_ER_Allred_B 10.243, confidence interval 1.97–57.97, P,0.01. C is the reference. (B) shows the RFS (in months, x-axis) for the three groups of progesterone (PR) Allred scores (A=0–2, B=3–5, C=6–8). There was statistically significant difference in RFS predicted for both the ER and PR groups (P=0.002 and P=0.013, respectively).